Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 478 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Botulinum Toxin Type A - OnabotulinumtoxinA Clear all

Conditions: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions: BOTOX, Placebo for BOTOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more

Conditions: Skin Aging
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Urinary Incontinence, Urinary Bladder, Overactive
Interventions: BOTOX®; Biological
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 8
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more

Conditions: Muscle Spasticity, Stroke
Interventions: onabotulinumtoxinA, placebo (normal saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Overactive Bladder
Interventions: botulinum toxin Type A, Normal Saline (Placebo); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: botulinum toxin Type A; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hyperhidrosis
Interventions: Microneedle, Sham Microneedle, Botulinum Toxin Type A, Saline; Device · Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Interventions: botulinum toxin neuromodulator, Placebo; Biological
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Encino, California • Santa Monica, California • West Hollywood, California + 8 more

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Overactive Bladder (OAB), Urge Incontinence
Interventions: onabotulinum toxin type a; Drug
Lead sponsor: Alexis Dieter; Other
Eligibility: 55 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Ischemia, Vasopressor
Interventions: Injection of botulinum toxin A; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sialorrhea
Interventions: MYOBLOC, PLACEBO; Drug · Other
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 24
States / cities: Loma Linda, California • Los Angeles, California • National City, California + 21 more

Conditions: Osteoarthritis
Interventions: onabotulinumtoxinA, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Artesia, California

Conditions: Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions: Abobotulinumtoxin-A, Control- Saline injection; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Post-stroke Spasticity of the Upper Limb
Interventions: IncobotulinumtoxinA (400 Units), Placebo Comparator; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Downey, California • Fountain Valley, California • Miami, Florida + 10 more

Conditions: Compartment Syndrome of Leg
Interventions: Botox; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Masseter Muscle Prominence
Interventions: OnabotulinumtoxinA, Normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Conditions: Glabellar Lines
Interventions: AGN-151586, BOTOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Glendale, Arizona • Newport Beach, California • Vista, California + 5 more

Conditions: Stroke
Interventions: Botox®, saline solution; Other
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Overactive Bladder, Bladder Pain Syndrome
Interventions: Nitrofurantoin 100 MG; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Dystonia
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, Normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 40
States / cities: Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more

Conditions: Hyperhidrosis
Interventions: botulinum toxin type A; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

The Use of Microneedles With Topical Botulinum Toxin for Treatment of Palmar Hyperhidrosis

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

Impact of Dysport on PMFF Donor Scar

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

Bladder Botox UTI Antibiotic Prophylaxis

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Study of Botulinum Toxin in Patients With Primary Hyperhidrosis